Avoid piperacillin-tazobactam when treating BSI cause by ceftriaxone-resistant pathogens

(European Society of Clinical Microbiology and Infectious Diseases) The antibiotic combination treatment piperacillin-tazobactam was significantly less effective than meropenem when treating potentially fatal bloodstream infections (BSI) caused by ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae and should be avoided when treating these organisms, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Source: EurekAlert! - Biology - Category: Biology Source Type: news